| Today | ||||
Kepler Cheuvreux analyst… Story temporarily locked. | ||||
Virtual meetings with… Story temporarily locked. | ||||
| Yesterday | ||||
Medtronic announced data… Medtronic announced data showing the benefits of the Symplicity Blood Pressure Procedure with the Symplicity Spyral Renal Denervation, or RDN, system on achieving target blood pressure level ranges. As part of the SPYRAL HTN Global Clinical Program, three-year data from SPYRAL HTN-ON MED and GSR-DEFINE were presented at EuroPCR 2022 as late-breaking clinical trials on May 17. Time in target range, or TTR, plays an important role in the management of many chronic diseases, such as diabetes and hypertension, measuring how well a parameter is controlled in patients. Specifically, for hypertension, increasing TTR has been shown to be an independent predictor of reductions in cardiovascular risks, including stroke, heart attack, and death. | ||||
Accuray (ARAY) announced… Accuray (ARAY) announced that Sandeep Chalke has joined the company as senior vice president, Chief Commercial Officer effective May 16. Chalke will have responsibility for the global commercial, product development, R&D and engineering functions for the company reporting to Accuray president and forthcoming CEO, Suzanne Winter. Chalke brings more than 25 years of medical device expertise in commercialization, business development and operations, spanning multiple healthcare industry segments including interventional catheterization systems, diagnostic x-ray, C-arm linear accelerators, anesthesia and respiratory care, advanced wound dressing & diabetes. Most recently, he served as president, Asia-Pacific and Latin America regions at Vyaire Medical, a global respiratory care manufacturer, where he had full P&L responsibility along with oversight of select manufacturing sites. Prior to Vyaire, Chalke held various global leadership positions at Medtronic (MDT), Acelity. and GE Healthcare, where he led the development of new products and service solutions, established new markets and partnerships with government organizations and private payors to drive revenue growth, margin expansion and technology leadership. | ||||
Citi analyst Joanne… Citi analyst Joanne Wuensch lowered the firm's price target on Zimmer Biomet to $125 from $135 and keeps a Neutral rating on the shares. Market multiples are contracting due to higher inflation, slowing growth, and rising interest rates, Wuensch tells investors in a research note. What we don't know yet is how far the derating will go and where does medical technology shake out, balancing an elective procedure recovery with macro headwinds, says the analyst. "When is the right time to catch a falling knife? If recent history is any suggestion, the answer could be 'soon,'" writes Wuensch. | ||||
Citi analyst Joanne… Citi analyst Joanne Wuensch lowered the firm's price target on Medtronic to $120 from $127 and keeps a Buy rating on the shares. Market multiples are contracting due to higher inflation, slowing growth, and rising interest rates, Wuensch tells investors in a research note. What we don't know yet is how far the derating will go and where does medical technology shake out, balancing an elective procedure recovery with macro headwinds, says the analyst. "When is the right time to catch a falling knife? If recent history is any suggestion, the answer could be 'soon,'" writes Wuensch. | |
Citi analyst Joanne… Citi analyst Joanne Wuensch lowered the firm's price target on Intuitive Surgical to $305 from $360 and keeps a Buy rating on the shares. Market multiples are contracting due to higher inflation, slowing growth, and rising interest rates, Wuensch tells investors in a research note. What we don't know yet is how far the derating will go and where does medical technology shake out, balancing an elective procedure recovery with macro headwinds, says the analyst. "When is the right time to catch a falling knife? If recent history is any suggestion, the answer could be 'soon,'" writes Wuensch. | |
Citi analyst Joanne… Citi analyst Joanne Wuensch lowered the firm's price target on Edwards Lifesciences to $115 from $134 and keeps a Buy rating on the shares. Market multiples are contracting due to higher inflation, slowing growth, and rising interest rates, Wuensch tells investors in a research note. What we don't know yet is how far the derating will go and where does medical technology shake out, balancing an elective procedure recovery with macro headwinds, says the analyst. "When is the right time to catch a falling knife? If recent history is any suggestion, the answer could be 'soon,'" writes Wuensch. | |
Citi analyst Joanne… Citi analyst Joanne Wuensch lowered the firm's price target on Abbott to $125 from $154 and keeps a Buy rating on the shares. Market multiples are contracting due to higher inflation, slowing growth, and rising interest rates, Wuensch tells investors in a research note. What we don't know yet is how far the derating will go and where does medical technology shake out, balancing an elective procedure recovery with macro headwinds, says the analyst. "When is the right time to catch a falling knife? If recent history is any suggestion, the answer could be 'soon,'" writes Wuensch. |
| Monday | ||||
Since the recall, the… Since the recall, the company has taken numerous measures to mitigate the supply shortage. Specifically, it has focused on production in its Cootehill, Ireland, facility to serve state Special Supplemental Nutrition Program for Women, Infants and Children consumers. Abbott has been working with the U.S. Department of Agriculture and WIC agencies and paying rebates on competitive products in states where Abbott holds the WIC contract, when Similac is not available. Abbott said Friday it will continue to pay rebates for competitive products through August 31. This means program participants will continue to be able to obtain formula free of charge, whether it is Similac or formula from another manufacturer. Additionally, the company has: Air shipped millions of cans of infant formula powder into the U.S. from our FDA-registered facility in Cootehill, Ireland. Prioritized infant formula production at our Columbus, Ohio, facility, converting other liquid manufacturing lines into manufacturing Similac liquid ready-to-feed and ramped production at our other U.S. manufacturing site in Casa Grande, Arizona, for powder infant formula. Offered an increased number and value of coupons available for all infant formula products, including Similac liquid ready-to-feed, to enable customers to purchase formula, either free or deeply discounted. Been running other facilities at full capacity to help replenish the supply in the market. | ||||
